Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor

Pharmacology Biochemistry and Behavior

Volumn 63, Issue 2, 1999, Pages 285-290

  Vaugeois, J M ^a   Corera, A T ^a   Deslandes, A ^b   Costentin, J ^a  

^a U de Neuropsychopharmacologie Exp   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

3H WIN 35,428 binding; Dopamine uptake inhibition; Locomotion; Mouse; Tianeptine

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMINEPTINE; ANTIDEPRESSANT AGENT; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; HALOPERIDOL; TIANEPTINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COCAINE; CORPUS STRIATUM; DEXTROAMPHETAMINE; DIBENZOCYCLOHEPTENES; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; HALOPERIDOL; MALE; MICE; MOTOR ACTIVITY; RADIOLIGAND ASSAY; THIAZEPINES;

EID: 0032958039     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00242-1     Document Type: Article

References (30)

1. Andrews N., File S.E. Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal. A review of supporting neurochemical and behavioral evidence Psychopharmacology (Berlin). 112:1993;21-25.
2. Ansseau M. The paradox of neurochemical and clinical properties of serotonergic antidepressants. Langer S.Z., Brunello N., Racagni G., Mendlewicz J. Critical issues in the treatment of affective disorders. 1994;127-135 Karger, Basel.
3. Arnt J. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats. Eur. J. Pharmacol. 113:1985;79-88.
4. Artigas F. Selective serotonin/noradrenaline reuptake inhibitors (SNRIs) - Pharmacology and therapeutic potential in the treatment of depressive disorders. CNS Drugs. 4:1995;79-89.
5. Blier P., Bergeron R. Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments. Are they related? Int. Clin. Psychopharmacol. 12(Suppl 3):1997;S21-S28.
6. Bonnet J.-J., Chagraoui A., Protais P., Costentin J. Interactions of amineptine with the neuronal dopamine uptake system. Neurochemical in vitro and in vivo studies J. Neural Transm. 69:1987;211-220.
7. Cassano G.B., Heinze G., Lôo H., Mendlewicz J., Paes de Sousa M. A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes. Eur. Psychiatry. 11:1996;254-259.
8. Costa e Silva J.A., Ruschel S.I., Caetano D., Rocha F.L., da Silva Lippi J.R., Arruda S., Ozun M. Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology. 35:1997;24-29.
9. Delbende C., Tranchand Bunel D., Tarozzo G., Grino M., Oliver C., Mocaer E., Vaudry H. Effect of chronic treatment with the antidepressant tianeptine on the hypothalamo-pituitary-adrenal axis. Eur. J. Pharmacol. 251:1994;245-251.
10. De Montis G.M., Devoto P., Gessa G.L., Meloni D., Porcella A., Saba P., Serra G., Tagliamonte A. Central dopaminergic transmission is selectively increased in the limbic system of rats chronically exposed to antidepressants. Eur. J. Pharmacol. 180:1990;31-35.
11. Duterte-Boucher D., Kamenka J.-M., Costentin J. Comparison of the effects of three indirect dopamine agonists, GK 13, GBR 12783 and dexamphetamine on behavioural tests involving central catecholaminergic transmissions. Psychopharmacology (Berlin). 101:1990;344-353.
12. Fattacini C.M., Bolanos-Jimenez F., Gozlan H., Hamon M. Tianeptine stimulates uptake of 5-hydroxytryptamine in vivo in the rat brain. Neuropharmacology. 29:1990;1-8.
13. Garcia de Mateos-Verchere J., Vaugeois J.-M., Naudin B., Costentin J. Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor. Eur. Neuropsychopharmacol. 8:1998;255-259.
14. Heikkila R.E. Differential effects of several dopamine uptake inhibitors and releasing agents on locomotor activity in normal and in reserpinized mice. Life Sci. 28:1981;1867-1873.
15. Invernizzi R., Pozzi L., Garattini S., Samanin R. Tianeptine increases the extracellular concentrations of dopamine in the nucleus accumbens by a serotonin-independent mechanism. Neuropharmacology. 31:1992;221-227.
16. Kelly J.P., Leonard B.E. The effect of tianeptine and sertraline in three animal models of depression. Neuropharmacology. 33:1994;1011-1016.
17. Labrid C., Moleyre J., Poignant J.-C., Malen C., Mocaer E., Kamoun A. Structure-activity relationships of tricyclic antidepressants, with special reference to tianeptine. Clin. Neuropharmacol. 11(Suppl. 2):1988;S21-S31.
18. Loo H., Deniker P. Position of tianeptine among antidepressive chemotherapies. Clin. Neuropharmacol. 11(Suppl. 2):1988;S97-S102.
19. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
20. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Bloom F.E., Kupfer D.J. Psychopharmacology. The fourth generation of progress:1995;933-944 Raven Press, New York.
21. Mennini T., Mocaer E., Garattini S. Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 336:1987;478-482.
22. Poignant J.-C. Etude pharmacologique d'un nouvel antidépresseur. La tianeptine Perris C., Struwe G., Jansson B. Biological psychiatry. 1981;573-578 Elsevier, Amsterdam.
23. Sacchetti G., Bonini I., Waeterloos G.C., Samanin R. Tianeptine raises dopamine and blocks stress-induced noradrenaline release in the rat frontal cortex. Eur. J. Pharmacol. 236:1993;171-175.
24. 3H WIN 35,428 Synapse. 4:1989;390-392.
25. Serra G., Collu M., D'Aquila P.S., Gessa G.L. Role of the mesolimbic dopamine system in the mechanism of action of antidepressants. Pharmacol. Toxicol. 71(Suppl. 1):1992;72-85.
26. Tanda G., Carboni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex. A trait of drugs with antidepressant potential? Psychopharmacology (Berlin). 115:1994;285-288.
27. Thiébot M.-H., Martin P., Puech A.J. Animal behavioural studies in the evaluation of antidepressant drugs. Br. J. Psychiatry Suppl. 15:1992;44-50.
28. Vaugeois J.-M., Bonnet J.-J., Duterte-Boucher D., Costentin J. In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur. J. Pharmacol. 230:1993;195-201.
29. Westerink B.H., Damsma G., de Vries J.B., Koning H. Dopamine re-uptake inhibitors show inconsistent effects on the in vivo release of dopamine as measured by intracerebral dialysis in the rat. Eur. J. Pharmacol. 135:1987;123-128.
30. Whitton P.S., Sarna G.S., Datla K.P., Curzon G. Effects of tianeptine on stress-induced behavioural deficits and 5-HT dependent behaviour. Psychopharmacology (Berlin). 104:1991;81-85.